Buy Wellbutrin (Bupropion) Online — Unique NDRI Atypical Antidepressant with No Sexual Side Effects or Weight Gain

📋 Wellbutrin essentials

Generic name

Bupropion hydrochloride (also bupropion hydrobromide as Aplenzin)

Brand names

Wellbutrin (immediate release), Wellbutrin SR (sustained release), Wellbutrin XL (extended release), Zyban (smoking cessation), Aplenzin (hydrobromide salt), Contrave (combination with naltrexone for weight loss)

Drug class

Norepinephrine-dopamine reuptake inhibitor (NDRI); aminoketone chemical class; unique among antidepressants

FDA-approved indications

Major depressive disorder (1985), Major depressive disorder seasonal pattern (Wellbutrin XL 2006), Smoking cessation (Zyban 1997)

Original manufacturer

Burroughs Wellcome; became Glaxo Wellcome then GlaxoSmithKline; extensive generic availability since 2006

Formulations

Wellbutrin IR tablets 75, 100 mg; Wellbutrin SR tablets 100, 150, 200 mg; Wellbutrin XL tablets 150, 300 mg; Zyban tablets 150 mg; Aplenzin 174, 348, 522 mg; Contrave 8/90 mg combination

Adult depression dose range

Wellbutrin IR: 100-450 mg divided TID; Wellbutrin SR: 150-400 mg BID; Wellbutrin XL: 150-450 mg once daily

Signature characteristics

Weight-neutral or weight-reducing (unique among antidepressants); minimal sexual dysfunction; activating (not sedating); no serotonergic effect; smoking cessation efficacy unique

💡 The unique-among-antidepressants positioning

Wellbutrin occupies distinctive position among antidepressants with characteristics essentially opposite to SSRIs: weight-neutral rather than weight-gaining; sexual function preserving rather than sexual dysfunction-inducing; activating rather than sedating; no serotonin syndrome risk. This distinctive profile makes bupropion valuable option for specific patient populations: (1) weight-conscious patients or those with obesity where weight gain problematic; (2) patients where sexual function is important consideration; (3) depression with prominent fatigue and low motivation where activation therapeutic; (4) SSRI-intolerant patients (sexual dysfunction, GI upset, activation); (5) SSRI augmentation for sexual dysfunction; (6) patients wanting smoking cessation alongside depression treatment (Zyban dual effect); (7) seasonal affective disorder (Wellbutrin XL FDA-approved). Combined with weight-neutral and sexual-function-preserving profile, bupropion often first-choice antidepressant for patients where these features are important. However, activating profile may worsen anxiety in some patients and seizure risk requires appropriate patient selection.

📅 Development timeline

1969-1970s

Burroughs Wellcome researchers synthesize bupropion as unique aminoketone; unrelated to existing antidepressant classes

December 1985

FDA approves bupropion as Wellbutrin for major depressive disorder - unique NDRI mechanism

1986

Voluntary withdrawal from market due to seizure concerns at higher doses (over 450 mg); post-marketing safety concerns emerging

1989

Reintroduced with lower dose limits (maximum 450 mg/day); revised prescribing information; seizure risk substantially reduced

Early 1990s

Growing recognition of distinctive tolerability profile - weight-neutral, minimal sexual dysfunction, activating - vs newly-launched SSRIs

1996

Wellbutrin SR (sustained-release) approved; twice-daily dosing; reduced peak concentrations and seizure risk

May 1997

Zyban approved by FDA for smoking cessation - first non-nicotine smoking cessation medication

1999

Jorenby NEJM landmark trial - bupropion vs nicotine patch vs combination for smoking cessation; established bupropion's smoking cessation role

2003

Wellbutrin XL (extended-release) approved - once-daily dosing; further improved convenience and side effect profile

2004-2007

FDA suicidality black box warnings extend to antidepressant class including bupropion

2006

Wellbutrin XL approved for major depressive disorder with seasonal pattern (SAD) - first antidepressant with SAD-specific FDA approval; Modell publication supports

2006

Generic bupropion widely available in United States

2008

Aplenzin (bupropion hydrobromide) approved as alternative salt formulation

2014

Contrave (bupropion + naltrexone) approved by FDA for chronic weight management - leveraged bupropion's weight-reducing potential

2016

Anthenelli Lancet EAGLES trial confirmed bupropion neuropsychiatric safety in smoking cessation; FDA removed Zyban boxed warning for smoking cessation indication (but retained for depression indication)

2010s-2020s

Continues among most-prescribed antidepressants globally; particular niche for weight-conscious, sexual-function-conscious patients, smoking cessation, and SAD

📌 Historical significance

• First aminoketone antidepressant - unique NDRI class
• Post-marketing safety refinement - 1986 withdrawal and 1989 reintroduction demonstrated pharmacovigilance in action
• First non-nicotine smoking cessation medication (Zyban 1997)
• First antidepressant with SAD-specific FDA approval (Wellbutrin XL 2006)
• Repositioned for weight management (Contrave 2014)
• EAGLES trial 2016 established neuropsychiatric safety in smoking cessation
• Extensive real-world data - four decades of clinical experience

💡 From safety refinement to established multi-indication drug

Bupropion's development illustrates successful pharmaceutical safety refinement process. Initial 1985 approval followed by 1986 withdrawal for seizure concerns demonstrated pharmacovigilance system working - manufacturer and FDA responded to real-world safety signals. 1989 reintroduction with lower dose limits (maximum 450 mg vs original higher doses) successfully reduced seizure risk to acceptable levels for depression treatment. Subsequent SR (1996) and XL (2003) formulations further reduced peak concentrations and seizure risk. Expansion to smoking cessation (1997), SAD (2006), and weight management (Contrave 2014) reflected recognition of bupropion's unique mechanistic profile beyond depression. Four decades of clinical experience have established bupropion among most-prescribed antidepressants globally with particular niches for patients requiring weight-neutral, sexual-function-preserving, or activating antidepressant profile. Understanding this historical evolution guides appropriate contemporary use.

⚗️ Structural features

Chemical name

1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride (bupropion HCl); alternatively as hydrobromide salt (Aplenzin)

Structural class

Aminoketone (specifically a cathinone derivative) - completely distinct from other antidepressant chemical classes (SSRIs, SNRIs, TCAs, tetracyclics)

Related compounds

Structurally related to diethylpropion (older anorectic/stimulant), cathinone (naturally occurring khat alkaloid), and other cathinone derivatives

Stereochemistry

Racemic mixture of R and S enantiomers; primary metabolite hydroxybupropion also exists as multiple stereoisomers

Molecular weight

Approximately 240 g/mol (bupropion HCl base)

Solubility

Water-soluble hydrochloride salt; lipophilic base; CNS penetration good

Salt forms

Hydrochloride (Wellbutrin) - most common; Hydrobromide (Aplenzin) - alternative

🔬 Receptor binding profile - NDRI signature

• Norepinephrine transporter (NET): moderate inhibitor; contributes to antidepressant effect and activation
• Dopamine transporter (DAT): moderate inhibitor; unique among antidepressants (though weak sertraline DAT effect exists); contributes to activation, motivation, smoking cessation
• Serotonin transporter (SERT): NO significant inhibition (unlike SSRIs); no serotonergic effect
• Nicotinic acetylcholine receptors: functional antagonist (particularly alpha4-beta2 subtype); basis for smoking cessation efficacy
• Muscarinic receptors: minimal binding; no anticholinergic effects
• Histamine H1 receptors: minimal binding; not sedating
• Alpha-1 adrenergic receptors: minimal binding
• Sodium channels: NO significant effect; unlike TCAs
• 5-HT receptors: minimal binding
• Active metabolite hydroxybupropion: contributes substantially to NET/DAT inhibition; more potent than parent for antidepressant effect

💡 The clean-and-distinctive receptor profile

Bupropion's receptor binding profile is remarkably clean - NET and DAT inhibition without significant off-target effects at muscarinic, histaminic, alpha-1, or sodium channels. This clean profile explains its distinctive tolerability: no anticholinergic effects, no sedation, no orthostatic hypotension, no cardiac conduction concerns typical of TCAs. The absence of serotonergic effect (no SERT inhibition) explains minimal sexual dysfunction, absence of GI upset (nausea, diarrhea) typical of SSRIs, and no serotonin syndrome risk. The nicotinic acetylcholine receptor antagonism (particularly alpha4-beta2 subtype) provides mechanism for smoking cessation - unique among antidepressants. Combined with active metabolite hydroxybupropion contributing to NDRI effect, bupropion provides distinctive dual monoamine (NE+DA without 5-HT) antidepressant plus smoking cessation efficacy through parallel mechanism. This mechanistic distinction from other antidepressant classes is fundamental to bupropion's clinical role.

🧠 Antidepressant mechanism

Norepinephrine reuptake inhibition

Moderate NET inhibition; increases NE availability in synaptic clefts; contributes to antidepressant and activation effects

Dopamine reuptake inhibition

Moderate DAT inhibition (unique among antidepressants); increases dopamine availability; contributes to motivation, energy, reward processing, sexual function preservation

Combined NDRI effect

Norepinephrine+dopamine enhancement without serotonin involvement; produces antidepressant effect through different mechanism than SSRIs/SNRIs

Active metabolite hydroxybupropion contribution

More potent NET inhibitor than parent bupropion; contributes substantially to sustained antidepressant effect; longer half-life supports once-daily XL dosing

Downstream adaptations

Weeks of chronic therapy: receptor adjustments; BDNF upregulation; neuroplasticity

Therapeutic effect timeline

Energy and motivation improvement early (first weeks); full antidepressant effect 4-6 weeks; SAD response 2-4 weeks typically

🚭 Smoking cessation mechanism

Nicotinic acetylcholine receptor antagonism

Functional antagonism at alpha4-beta2 nicotinic receptors - primary receptor mediating nicotine addiction; reduces nicotine reward and craving

Dopamine reuptake inhibition

DAT inhibition provides tonic dopamine enhancement in nucleus accumbens; reduces withdrawal-related dysphoria and craving

Norepinephrine effect

Reduces withdrawal-related anxiety and difficulty concentrating

Clinical evidence

Jorenby 1999 NEJM landmark trial demonstrated approximately doubled abstinence rates vs placebo; effective as monotherapy or combined with nicotine replacement

Time course

Start 1-2 weeks before quit date; craving reduction from early therapy; 7-12 weeks total treatment typical

🎯 Mechanism-condition mapping

Major depressive disorder

Combined NDRI effect through NE and DA enhancement; 4-6 weeks for full effect

Seasonal affective disorder

Wellbutrin XL FDA-approved; likely dopamine-mediated effect on seasonal fatigue and hyperphagia; 2-4 weeks response

Smoking cessation

Nicotinic antagonism + DA enhancement; craving reduction

Sexual function preservation

Absence of serotonergic effect + DA enhancement (dopamine promotes sexual response); minimal sexual dysfunction

SSRI sexual dysfunction augmentation

DA enhancement may counteract SSRI sexual side effects; established augmentation strategy

Weight-neutral profile

Absence of histamine H1 antagonism (no appetite stimulation); dopamine effect on reward may reduce food-seeking

ADHD (off-label)

NDRI effect similar to stimulant mechanism (though weaker); non-controlled substance alternative for adult ADHD

💡 The dopamine advantage

Bupropion's dopamine reuptake inhibition is fundamental to its distinctive clinical profile. Unlike SSRIs which enhance only serotonin, bupropion's DA enhancement provides several unique advantages: (1) motivation and energy improvement (dopamine central to motivational states); (2) smoking cessation efficacy (nicotine reward mediated by dopamine); (3) sexual function preservation (dopamine promotes sexual response, contrary to serotonin's inhibitory effect); (4) weight-neutral profile (dopamine reward reduces compensatory eating; no histamine appetite stimulation); (5) ADHD off-label utility (similar mechanism to stimulants though weaker). This dopamine component distinguishes bupropion from other antidepressants and explains why patients who don't respond to SSRIs may respond to bupropion - different neurotransmitter system engagement. However, dopamine activation may also worsen anxiety in some patients and contributes to some concerns like insomnia. Understanding this dopamine-focused mechanism guides appropriate patient selection.

🔬 PK parameters

Absorption

Well-absorbed orally; Tmax approximately 2 hours (IR), 3 hours (SR), 5 hours (XL); food modestly increases exposure

Bioavailability

Substantial first-pass metabolism; parent drug bioavailability moderate but active metabolite provides substantial systemic exposure

Protein binding

Approximately 84 percent (parent); 77 percent (hydroxybupropion metabolite)

Volume of distribution

Very large: approximately 20-45 L/kg; extensive tissue distribution

Half-life

Bupropion parent approximately 14-21 hours; active metabolite hydroxybupropion approximately 20 hours; substantial contribution from metabolite in sustained clinical effect

Steady-state

Reached in approximately 8 days

Metabolism - unique CYP2B6

CYP2B6 primary (produces active hydroxybupropion); minor CYP1A2, CYP3A4 contribution; UNIQUE among antidepressants - most others use CYP2D6 or CYP3A4 primarily

Active metabolite - hydroxybupropion

Substantially contributes to clinical effect; MORE potent NET inhibitor than parent bupropion; longer half-life provides sustained effect

Elimination

Primarily renal excretion of metabolites; less than 1 percent unchanged parent

🧬 CYP2B6 pharmacogenomics - unique consideration

CYP2B6 polymorphism

Substantial genetic variation in CYP2B6 activity; poor metabolisers approximately 4-6 percent of population; ultra-rapid metabolisers also exist

Impact on bupropion

Poor metabolisers have higher parent bupropion levels but lower hydroxybupropion levels; different balance of parent vs metabolite effect

CYP2B6 inhibitors and inducers

Fewer known interactions than CYP2D6/3A4; ticlopidine, clopidogrel inhibit CYP2B6; rifampin, phenobarbital induce

Interaction resistance advantage

Because most drug interactions involve CYP2D6/3A4/1A2 rather than CYP2B6, bupropion has relatively few metabolic interaction concerns FROM other drugs

Bupropion as CYP2D6 inhibitor

POTENT CYP2D6 inhibitor (comparable to paroxetine/fluoxetine); substantial effects on OTHER drugs metabolized by CYP2D6 (TCAs, some beta-blockers, tamoxifen, codeine)

💡 The metabolism uniqueness

Bupropion's CYP2B6 primary metabolism is unique among antidepressants and provides interesting clinical implications: (1) bupropion levels are less affected by drugs that inhibit CYP2D6 or CYP3A4 (most common inhibitor pathways); (2) however, bupropion is potent CYP2D6 inhibitor itself, affecting other drugs; (3) tamoxifen combination problematic (bupropion CYP2D6 inhibition reduces tamoxifen effectiveness - similar concern to paroxetine); (4) codeine, tramadol combined with bupropion produce reduced opioid analgesic effect (both require CYP2D6 for activation to active metabolites); (5) TCAs combined with bupropion require substantial dose reduction. The active metabolite hydroxybupropion contributes substantially to clinical effect - accounts for majority of NET inhibition and provides sustained response supporting once-daily XL dosing. Understanding these PK considerations guides appropriate combination therapy and monitoring.

📌 Off-label uses

• ADHD in adults (off-label) - NDRI mechanism similar to stimulants; non-controlled substance option
• SSRI-induced sexual dysfunction augmentation - Clayton research supports adding bupropion to SSRI
• SSRI treatment-resistant depression augmentation - complementary mechanism to SSRI
• Weight loss with SSRI-induced weight gain - counteract SSRI weight effects
• Bipolar depression (with mood stabilizer) - lower switch risk than TCAs though still requires stabilizer
• Anxious depression with fatigue (cautiously) - activating effect may help fatigue but can worsen anxiety
• Cocaine/stimulant use disorder (limited evidence) - some benefit reported
• Post-stroke depression - alternative to SSRI
• Neuropathic pain (limited evidence)

💡 The multi-indication versatility

Bupropion's three distinct FDA indications reflect its unique multi-mechanism profile - NDRI effects for depression and SAD, nicotinic antagonism + NDRI for smoking cessation. This versatility enables single medication to address multiple concurrent conditions: depression + smoking (common comorbidity given depression associates with tobacco use); depression + weight concerns (weight-neutral advantage); SAD + smoking cessation (unusual but possible combination). Modern practice frequently uses bupropion across these indications and its off-label roles including sexual dysfunction management. Combined with distinct tolerability profile from other antidepressant classes, bupropion often selected specifically for its unique attributes rather than as SSRI alternative. This positioning as first-choice medication for specific clinical situations distinguishes bupropion from many antidepressants used primarily as second-line alternatives.

🧩 Bupropion in MDD

Efficacy positioning

Cipriani 2018 includes bupropion among effective antidepressants; Papakostas 2007 meta-analysis comparable to SSRIs; established efficacy

Response rate

Approximately 55-65 percent response; comparable to SSRIs; similar remission rates

Onset of effect

Energy and motivation improvement early (first weeks); 2-4 weeks initial mood improvement; 4-6 weeks full effect

Dosing for depression

Wellbutrin XL: start 150 mg once daily; increase to 300 mg after 4 days if tolerated; maximum 450 mg. Wellbutrin SR: start 150 mg once daily then 150 mg BID; maximum 400 mg BID divided. Wellbutrin IR: start 100 mg BID then TID; maximum 450 mg

Guideline positioning

CANMAT, WFSBP, BAP include bupropion as first-line antidepressant option; particularly recommended when SSRI adverse effects concerning

🌟 Depression scenarios where Wellbutrin ideal first-line

• Depression with prominent fatigue and low energy: activation therapeutic
• Depression with low motivation, apathy: dopamine effect
• Weight-concerned patients or obesity: weight-neutral to weight-reducing profile
• Sexual function important: minimal sexual dysfunction (5-10 percent vs SSRI 30-50 percent)
• Depression with concurrent smoking (want to quit): dual benefit addresses both
• Seasonal affective disorder: Wellbutrin XL FDA-approved; hyperphagia and hypersomnia particularly targeted
• SSRI-intolerant patients: different mechanism, different side effect profile
• Depression with somnolence: activation counter-effect
• Diabetic patients: weight-neutral important
• Metabolic syndrome: weight neutrality
• Working professionals valuing daytime function: no sedation

💡 The unique-among-antidepressants MDD positioning

Wellbutrin's positioning for MDD reflects both efficacy (comparable to SSRIs per Papakostas 2007 meta-analysis) and distinctive tolerability profile. For patients where SSRI adverse effects (weight gain, sexual dysfunction, sedation, GI upset) would be problematic, bupropion often represents ideal first-line choice rather than second-line after SSRI trial. Modern practice increasingly recognizes tolerability-guided antidepressant selection: bupropion for weight-concerned or sexual-function-concerned patients; mirtazapine for insomnia+depression; sertraline for general first-line; duloxetine for pain comorbidity. This targeted approach can produce faster response and better adherence than one-size-fits-all approach. However, bupropion has limitations: activation may worsen anxiety in some patients (avoid for anxious depression); seizure risk requires careful patient selection; contraindicated in eating disorders; not appropriate for patients requiring sedation. Understanding both advantages and limitations guides appropriate patient selection.

☃️ Wellbutrin XL in SAD

FDA approval significance

First antidepressant with FDA-specific SAD approval (2006); prior SSRIs used off-label for SAD

Evidence base

Modell 2005 landmark trial for prevention of seasonal MDD episodes; Lam CANMAT guidelines recommend bupropion XL for SAD prevention and treatment; Wirz-Justice chronobiology research supports

SAD typical features

Winter depression with atypical features: hypersomnia (excessive sleep), hyperphagia (increased appetite/weight gain, carbohydrate craving), fatigue, low motivation - opposite of typical melancholic depression

Why bupropion ideal

Activation counteracts hypersomnia and fatigue; weight-neutral to weight-reducing counteracts hyperphagia and weight gain; dopamine effect on reward may counteract seasonal apathy and anhedonia

Dosing for SAD prevention

Wellbutrin XL 150 mg once daily in autumn before typical seasonal depression onset; increase to 300 mg if needed; continue through winter until spring

Duration of treatment

Typically start in autumn 1-3 months before typical onset; continue through winter; taper in spring or continue year-round based on individual pattern

Response rate

Substantially reduced SAD episode occurrence in prevention studies; effective for treatment of established SAD episodes

🎯 SAD treatment framework

• Bright light therapy first-line: 10,000 lux for 30 minutes morning; strongest SAD evidence base; Terman and Wirz-Justice research
• Wellbutrin XL prophylaxis: FDA-approved; particularly useful when light therapy inadequate or inconvenient
• SSRIs: off-label but effective for SAD (sertraline, escitalopram); alternative when bupropion contraindicated
• Combined bupropion + light therapy: synergistic approach for severe SAD
• CBT for SAD (CBT-SAD): Rohan and colleagues; psychological approach with evidence base
• Vitamin D supplementation: modest evidence; low risk
• Chronotherapy approaches: Wirz-Justice research; adjunctive
• Combined maintenance year-round: some patients require year-round therapy given SAD chronicity

💡 The SAD-perfect medication

Bupropion's profile is essentially perfect for SAD treatment: activation counteracts SAD hypersomnia and fatigue (unlike sedating SSRIs like paroxetine which could worsen sleepiness); weight-neutral to reducing counteracts SAD weight gain and carbohydrate craving (unlike SSRIs which cause weight gain); dopamine effect on reward and motivation counteracts anhedonia. Wellbutrin XL FDA approval for SAD prevention makes bupropion uniquely positioned among antidepressants for this indication. Lam's CANMAT guidelines and Wirz-Justice chronobiology research support this positioning. For patients with clear SAD pattern, autumn initiation of Wellbutrin XL 150-300 mg represents evidence-based prevention approach. Combined with bright light therapy (strongest overall SAD evidence per Terman and colleagues), combined approach provides comprehensive SAD management. For year-round SAD sufferers or those with treatment-resistant SAD, continuous therapy may be appropriate. Understanding bupropion's unique SAD-appropriate profile guides evidence-based seasonal depression management.

🚭 Zyban for smoking cessation

FDA approval May 1997

Bupropion SR 150 mg approved as Zyban for smoking cessation - first non-nicotine smoking cessation medication

Evidence base

Hurt 1997 initial approval trial; Jorenby NEJM 1999 landmark trial (bupropion vs nicotine patch vs combination); substantially doubled abstinence rates vs placebo

Mechanism

Nicotinic acetylcholine receptor antagonism (alpha4-beta2) + dopamine reuptake inhibition; reduces nicotine reward and craving

Efficacy vs alternatives

Approximately doubles 6-month abstinence rates vs placebo; comparable to nicotine patch monotherapy; combination therapy (bupropion + NRT) may be more effective than either alone; varenicline may be more effective than bupropion monotherapy

Dosing

Start 1-2 weeks BEFORE quit date; 150 mg once daily x 3 days, then 150 mg BID at least 8 hours apart; continue 7-12 weeks total

Duration

7-12 weeks standard; may extend to 6 months for maintenance in some patients

EAGLES trial neuropsychiatric safety

Anthenelli Lancet 2016 EAGLES trial demonstrated neuropsychiatric safety of bupropion in smoking cessation; FDA removed Zyban boxed warning for smoking cessation indication 2016 (though retained for depression indication)

🌟 Zyban ideal candidates

• Motivated smokers seeking to quit: appropriate patient selection
• Smokers who prefer oral medication over nicotine replacement: alternative to NRT
• Smokers with concurrent depression: dual benefit for both conditions with single medication
• Smokers who failed nicotine replacement: different mechanism
• Smokers with weight concerns about quitting: bupropion weight-neutral effect helps mitigate quit-related weight gain
• Combined with counselling: substantially improved outcomes; USPHS guideline recommendation

🎯 Smoking cessation treatment framework

• USPHS Guideline (Fiore Chair): recommends bupropion SR, nicotine replacement therapy (NRT), and varenicline as first-line
• Nicotine replacement therapy (NRT): patches, gum, lozenges, inhaler, nasal spray
• Varenicline (Chantix): partial nicotinic agonist; may be more effective than bupropion monotherapy
• Bupropion SR (Zyban): first-line pharmacotherapy; particularly useful when NRT insufficient or contraindicated
• Combined therapy: bupropion + NRT more effective than either alone
• Behavioral counselling: substantial addition to pharmacotherapy; Rigotti research supports combined approach
• Quitline support: telephone counselling; often free through state programs
• Follow-up critical: relapse common; ongoing support improves outcomes

💡 The smoking cessation dual benefit opportunity

Bupropion's smoking cessation efficacy is particularly valuable given substantial overlap between depression and smoking (depressed patients smoke at higher rates; smoking cessation attempts commonly precipitate depression). Single medication addressing both conditions represents efficient therapeutic approach. Rigotti and Fiore research supports this integrated approach - treating depression with bupropion in smoker naturally facilitates smoking cessation. Modern practice for depressed smokers should routinely address smoking cessation - bupropion provides opportunity to accomplish both goals. Anthenelli EAGLES trial 2016 provided reassurance about neuropsychiatric safety in smoking cessation - concerns about bupropion in early Zyban post-marketing period have been resolved. Combined with behavioural counselling and long-term follow-up, bupropion provides evidence-based smoking cessation treatment. For most depressed smokers, bupropion represents ideal antidepressant choice given dual therapeutic mechanism.

🧠 Adult ADHD (off-label)

Rationale

NDRI mechanism similar to stimulants (methylphenidate, amphetamines); may improve attention and focus

Advantages vs stimulants

Non-controlled substance; no diversion or abuse concerns; can be prescribed by any physician; less activation than stimulants; less appetite suppression concerns

Efficacy

Less effective than stimulants but reasonable alternative; particularly useful for adults with concurrent depression + ADHD or contraindications to stimulants

Dosing

Similar to depression dosing (Wellbutrin XL 300 mg typically)

❤️ SSRI-induced sexual dysfunction augmentation

Rationale

Dopamine enhancement counteracts serotonin-mediated sexual dysfunction; established Clayton research supports

Approach

Add bupropion 150-300 mg XL to SSRI patient experiencing sexual dysfunction while maintaining SSRI antidepressant efficacy

Efficacy

Substantial improvement in SSRI-induced sexual dysfunction for many patients; may also enhance antidepressant response (dual-mechanism benefit)

Alternative

PDE-5 inhibitors (sildenafil) for men with erectile dysfunction as alternative or adjunct

📌 Other off-label uses

• Treatment-resistant depression augmentation: added to SSRI for enhanced antidepressant effect (California rocket fuel involves mirtazapine but bupropion+SSRI is common alternative)
• Weight loss with SSRI-induced weight gain: counteract SSRI weight effects
• Bipolar depression (with mood stabilizer): lower mania switch risk than TCAs though still requires stabilizer
• Post-stroke depression: alternative to SSRI
• Cocaine/stimulant use disorder: limited evidence; theoretical benefit from dopamine modulation
• Neuropathic pain (limited evidence)
• Chronic fatigue syndrome: some patients benefit from activation
• Attention/concentration difficulties from other causes
• Anhedonia: dopamine effect on reward may address

💡 The versatile NDRI applications

Bupropion off-label utility reflects the versatile NDRI mechanism. For SSRI-induced sexual dysfunction, bupropion augmentation (Clayton research) provides evidence-based approach maintaining SSRI antidepressant benefit while addressing sexual side effects. For adult ADHD, bupropion offers non-controlled-substance alternative to stimulants, particularly useful for patients with concurrent depression or stimulant contraindications. For treatment-resistant depression, bupropion + SSRI combination targets complementary mechanisms. For anhedonia and low motivation specifically (increasingly recognized as important depression dimension), dopamine effect may be particularly valuable. Combined with formal FDA indications, bupropion's off-label uses further expand its clinical utility.

💊 Contrave for chronic weight management

FDA approval September 2014

Contrave (bupropion 90 mg + naltrexone 8 mg per tablet) approved for chronic weight management in adults with BMI 30+ or BMI 27+ with weight-related comorbidity

Mechanism

Bupropion (NDRI): dopamine effect on reward reduces food-seeking; norepinephrine effect on energy expenditure. Naltrexone (opioid receptor antagonist): reduces food cravings and reward from eating; blocks opioid feedback on POMC neurons

Combined mechanism advantage

Bupropion activates POMC neurons producing anorexigenic effect; naltrexone blocks endogenous opioid feedback that would otherwise reduce POMC activation; synergistic weight loss effect

Dosing (weekly titration)

Week 1: 1 tablet morning; Week 2: 1 tablet BID; Week 3: 2 tablets morning + 1 evening; Week 4+: 2 tablets BID (32 mg naltrexone + 360 mg bupropion daily maximum)

Efficacy

Approximately 4-6 percent additional weight loss vs placebo at 1 year; combined with lifestyle intervention

Discontinuation if inadequate response

If less than 5 percent weight loss at 12 weeks, discontinue (unlikely to succeed with continued therapy)

Contrave contraindications

Uncontrolled hypertension, seizure disorder (bupropion component), current or prior eating disorder (bupropion), chronic opioid use (naltrexone precipitates withdrawal), MAOI, alcohol/benzo withdrawal, pregnancy

💡 The bupropion weight management application

Contrave represents unique application of bupropion's weight-neutral to weight-reducing properties in dedicated weight management context. The bupropion+naltrexone combination provides synergistic weight loss through complementary mechanisms addressing both food-seeking (bupropion) and food reward (naltrexone). For appropriate obese patients or overweight patients with comorbidities, Contrave provides evidence-based pharmacotherapy adjunct to lifestyle intervention. The concept that bupropion's dopaminergic properties can be leveraged for weight management alongside its antidepressant utility illustrates the versatile clinical applications of NDRI mechanism. However, Contrave contraindications largely overlap with bupropion contraindications - seizure history, eating disorders, MAOI. Combined with appropriate patient selection and lifestyle intervention, Contrave provides useful weight management option.

🌟 When each formulation preferred

• Wellbutrin XL: preferred for depression maintenance (once-daily adherence); required for SAD indication; best seizure risk profile
• Wellbutrin SR: alternative BID dosing; Zyban formulation for smoking cessation; may be less expensive than XL in some formularies
• Wellbutrin IR: rarely used in modern practice; historical; TID dosing reduces adherence; higher seizure risk with higher peaks
• Contrave: specific weight management combination product
• Aplenzin: bupropion hydrobromide alternative; different strengths for equivalent dosing (174, 348, 522 mg vs 150, 300, 450 mg HCl)

💡 The formulation selection practical guide

Modern bupropion prescribing typically uses Wellbutrin XL for depression (once-daily adherence, best seizure risk profile, FDA SAD approval) or Zyban SR for smoking cessation. Wellbutrin SR remains useful when XL not covered by insurance or specific BID dosing pattern preferred. Wellbutrin IR (immediate release) is rarely used in modern practice - TID dosing reduces adherence and higher peak concentrations increase seizure risk. For patients requiring dose flexibility, SR provides more granular dose options (100/150/200 mg) than XL (150/300 mg only). For patients concerned about seizure risk (especially at higher doses), XL provides smoothest kinetics. For smoking cessation specifically, Zyban SR is standard formulation. Understanding formulation differences guides appropriate prescribing decisions.

📊 Critical dosing principles

Morning dosing standard

Activating profile means morning dosing reduces insomnia risk; avoid evening/bedtime dosing

450 mg absolute maximum

Never exceed 450 mg/day total across any formulation - seizure risk substantially increases above this dose

Single dose limit for IR

Never exceed 150 mg single dose IR (higher peak concentrations increase seizure risk)

8-hour minimum interval SR

SR BID dosing requires at least 8 hours between doses; typical morning and afternoon (not late evening)

Titration approach

Standard titration 150 mg for 3-4 days then increase to reduce initial adverse effects (insomnia, anxiety)

Response assessment

Energy/motivation improvement early (1-2 weeks); depression response 4-6 weeks; SAD response 2-4 weeks; smoking cessation begins with early therapy

Duration

Depression: continue effective dose 6-12 months minimum; SAD: through winter season; smoking cessation: 7-12 weeks; weight management: assessed at 12 weeks

💡 The seizure-avoidance dosing principle

Bupropion dosing rules are shaped substantially by seizure risk management. The 450 mg absolute maximum (originally set after 1986 withdrawal for seizures at higher doses) applies across all formulations and indications. The IR single-dose limit (150 mg maximum) prevents high peak concentrations. The SR 8-hour interval prevents overlapping peaks. Morning dosing avoids evening/bedtime timing that would exacerbate insomnia. These formulation-specific rules combine to substantially reduce seizure risk while maintaining efficacy. Combined with appropriate patient selection (avoiding seizure disorders, eating disorders, alcohol/benzo withdrawal states), bupropion can be used safely across its multiple indications. Understanding these dose-safety principles guides safe prescribing.

🧒 Pediatric considerations

FDA approval status

Not FDA-approved for any pediatric indication; all pediatric use off-label

Black box warning applies

Suicidality warning for antidepressants; particular concern under age 25

Pediatric depression

Fluoxetine (FDA-approved age 8+) and escitalopram (adolescents) preferred first-line; bupropion off-label alternative

Adolescent ADHD (off-label)

Stimulants (methylphenidate, amphetamines) and atomoxetine FDA-approved; bupropion off-label alternative when stimulants contraindicated or intolerable

Adolescent smoking cessation

Zyban not approved for pediatric use; behavioural approaches preferred for adolescent smokers

Seizure risk in adolescents

Similar seizure risk as adults; contraindications for eating disorders particularly relevant given prevalence in adolescent population

🔴 Pediatric-specific concerns

• Suicidality black box: highest concern under age 25; family awareness essential
• Eating disorder contraindication: substantial concern given adolescent eating disorder prevalence; must rule out anorexia and bulimia before initiation
• Seizure risk: dose limits particularly important in pediatric patients
• Activation may worsen anxiety: adolescent depression often has anxiety comorbidity
• Behavioural activation: mania, aggression possible; monitor
• School functioning: assess academic performance; activation may help or worsen depending on individual
• Family involvement: critical for pediatric use
• Specialist involvement: pediatric psychiatry when possible

💡 The pediatric off-label positioning

Bupropion pediatric use is generally limited given availability of FDA-approved alternatives. For pediatric depression, fluoxetine is preferred (FDA-approved, extensive pediatric evidence). For pediatric ADHD, stimulants are preferred (FDA-approved, high efficacy). For adolescent smoking cessation, behavioural approaches preferred over pharmacotherapy given adolescent brain development. Bupropion may be considered off-label for adolescents with: (1) treatment-resistant depression not responding to SSRIs; (2) adolescent ADHD with stimulant contraindications or intolerance; (3) depression with concurrent smoking motivation. Rule out eating disorders essential before initiation (contraindication). Specialist involvement (pediatric psychiatry) preferred. Family education about black box warning and warning signs critical. For most pediatric psychiatric conditions, better-supported alternatives to bupropion exist.

👴 Bupropion advantages in elderly

Not on Beers inappropriate list

Unlike paroxetine (only SSRI on Beers inappropriate), amitriptyline, doxepin high-dose - bupropion acceptable elderly

Weight-neutral advantage

Particularly valuable for elderly where SSRI weight gain may worsen metabolic health, mobility, joint problems

Minimal anticholinergic effects

Unlike TCAs and paroxetine; preserves cognition; less falls risk; less urinary retention

No sedation

Preserves daytime function; unlike sedating alternatives (TCAs, mirtazapine, paroxetine)

No orthostatic hypotension

Unlike TCAs; important for fall prevention in elderly

Cognitive preservation

Activating profile may improve rather than worsen cognitive function; important consideration for elderly

Favourable overdose profile

Safer than TCAs in overdose; important given elderly potentially accidental double-dosing

⚠️ Elderly considerations

• Insomnia may be problematic: activation may worsen elderly sleep disturbance
• Anxiety may be worsened: activating effect problematic if anxiety comorbidity
• Seizure risk: still applies to elderly; assess seizure history; watch for concurrent seizure-lowering medications
• Blood pressure monitoring: modest BP elevation possible; important elderly cardiovascular monitoring
• Reduced starting doses: start 150 mg XL (not higher); slower titration in elderly
• Drug interactions: bupropion's CYP2D6 inhibition affects many medications elderly commonly take

💡 The elderly niche

For elderly depression, bupropion often represents excellent choice given weight-neutral profile, minimal anticholinergic effects, no sedation, no orthostatic hypotension, and Beers-acceptable positioning. Alternatives include sertraline (SSRI, Beers-acceptable), escitalopram (Beers-acceptable), mirtazapine (if insomnia+appetite loss). Paroxetine avoided (Beers inappropriate), amitriptyline avoided (Beers inappropriate); TCAs generally avoided. For elderly depression with prominent fatigue, apathy, and low motivation, bupropion's dopaminergic effect may be particularly beneficial. For elderly with concurrent smoking wishing to quit, dual benefit particularly attractive. For SAD in elderly (common in older adults with winter depression), Wellbutrin XL provides FDA-approved option. Combined with careful patient selection (avoiding seizure history, active anxiety, insomnia patients), bupropion provides excellent elderly antidepressant option.

🫀 Renal impairment approach

Elimination pathway

Primarily hepatic metabolism to active metabolites; metabolites (hydroxybupropion primarily) renally excreted; metabolite accumulation in renal impairment

Mild renal impairment

Modest dose reduction may be considered; monitor for adverse effects

Moderate renal impairment

Reduce dose; consider maximum 300 mg XL rather than 450 mg

Severe renal impairment

Substantial dose reduction; consider maximum 150 mg XL daily; monitor closely for accumulation

Dialysis

Limited data; not effectively removed by dialysis; supplemental doses generally not needed

Seizure risk elevated

Metabolite accumulation may increase seizure risk in severe renal impairment; dose reduction reduces this concern

💡 The renal considerations

Bupropion in renal impairment requires attention given active metabolites (particularly hydroxybupropion) undergo renal excretion. Dose reduction based on impairment severity manages accumulation and seizure risk. For patients requiring depression treatment in severe CKD, sertraline or escitalopram may be preferred first-line given straightforward PK in renal impairment. However, bupropion remains reasonable option in mild-moderate renal impairment with appropriate dose adjustment. Combined with weight-neutral advantage (particularly relevant for CKD patients often struggling with weight and metabolic health) and minimal anticholinergic effects, bupropion may provide useful CKD depression option.

🪶 Hepatic impairment approach

Metabolism dependence

Extensive hepatic CYP2B6 metabolism; hepatic impairment substantially reduces clearance

Mild hepatic impairment (Child-Pugh A)

Modest dose reduction; monitor closely

Moderate-severe hepatic impairment (Child-Pugh B or C)

Maximum 150 mg every OTHER day for Wellbutrin XL (substantial reduction); 100 mg IR every other day; approach conservatively

Alternative consideration

For substantial hepatic impairment, sertraline or mirtazapine may be preferred antidepressants with somewhat cleaner PK profiles

Alcohol considerations

Chronic alcohol use often present in hepatic impairment; abrupt withdrawal contraindicated with bupropion (seizure risk); careful history essential

Cirrhosis considerations

Substantial exposure increases; strict dose limits; monitor for excessive activation, insomnia, anxiety

💡 Hepatic impairment individualized approach

Bupropion in moderate-severe hepatic impairment requires substantial dose reduction and careful monitoring. Every-other-day dosing recommendation reflects reduced clearance. For patients with substantial hepatic impairment, alternatives with simpler PK profile may be preferred. Chronic alcohol use often present in hepatic impairment patients is important consideration - bupropion contraindicated in abrupt alcohol withdrawal due to seizure risk; careful history essential to rule out active alcohol use disorder. Combined with hepatologist involvement and careful monitoring, bupropion can be used cautiously in hepatic impairment when clinical need justifies.

🚫 Absolute contraindications

• MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline): severe hypertensive reactions possible; 14-day washout both directions
• Linezolid, IV methylene blue: MAOI-like activity; hypertensive reactions
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates: withdrawal states lower seizure threshold; bupropion contraindicated during active withdrawal
• Ritonavir combined with efavirenz: substantially increases bupropion levels via CYP2B6 effects; avoid

🧬 CYP2D6 inhibition - bupropion affects OTHER drugs

Bupropion potent CYP2D6 inhibitor

Similar to paroxetine and fluoxetine in CYP2D6 inhibition potency; substantially affects other medications requiring CYP2D6

Tricyclic antidepressants

Substantially increased TCA levels; TCA dose reduction 50-70 percent typically needed; TDM guidance useful

Codeine, tramadol, hydrocodone

These opioids require CYP2D6 activation to active metabolites; bupropion reduces analgesic effectiveness; alternative opioid selection (morphine, hydromorphone) needed

Tamoxifen - critical concern

Bupropion CYP2D6 inhibition reduces tamoxifen activation to endoxifen (active metabolite); may reduce breast cancer treatment effectiveness; similar concern to paroxetine; alternative antidepressants (venlafaxine, escitalopram) preferred for breast cancer patients on tamoxifen

Beta-blockers (metoprolol, propranolol)

Increased levels; enhanced bradycardia and hypotension effects; may need dose reduction

Antipsychotics (haloperidol, risperidone, aripiprazole)

Increased levels; enhanced extrapyramidal effects

Atomoxetine (Strattera)

Substantially increased levels; ADHD medication dose adjustment needed

⚠️ Seizure threshold concerns

• Antipsychotics: additive seizure threshold lowering; caution with combinations
• Tramadol: substantially lowers seizure threshold; combination with bupropion increases seizure risk substantially
• Other antidepressants: additive seizure threshold effects
• Theophylline, systemic steroids: seizure threshold lowering
• Antimalarials, quinolones: additive concerns
• Abrupt alcohol/benzodiazepine/barbiturate withdrawal: absolute contraindication as noted above

⚠️ Other interactions

• Warfarin: modest interaction possible; INR monitoring
• Digoxin: reduced digoxin levels possible
• CYP2B6 inducers (rifampin, phenobarbital, phenytoin, carbamazepine): may reduce bupropion levels
• Ticlopidine, clopidogrel: CYP2B6 inhibition may increase bupropion levels
• Nicotine transdermal: modest BP elevation possible; combination often used for smoking cessation but monitor BP

💡 The CYP2D6 inhibition awareness

Bupropion's potent CYP2D6 inhibition (comparable to paroxetine, fluoxetine) is often underappreciated because bupropion is not commonly thought of as CYP inhibitor. However, this inhibition substantially affects many medications: TCAs (dose reduction needed), codeine/tramadol/hydrocodone (reduced analgesia), tamoxifen (reduced anticancer effectiveness - major concern), beta-blockers, some antipsychotics, atomoxetine. For breast cancer patients on tamoxifen, bupropion should be avoided similar to paroxetine (use venlafaxine or escitalopram instead). For chronic pain patients on codeine/tramadol/hydrocodone, alternative opioid selection needed. Combined with seizure threshold contraindications (particularly alcohol/benzo withdrawal), bupropion prescribing requires careful medication history and awareness of these interaction patterns.

🤰 Pregnancy considerations

FDA pregnancy category (former)

Category C; FDA transitioned to descriptive labelling; NOT Category D like paroxetine

Malformation risk

Louik 2007 and other studies do not show substantially increased major malformation risk; some early studies suggested possible cardiac malformation signal but not consistently replicated

Chun-Fai-Chan et al 2005

Pregnancy outcomes with bupropion generally reassuring for first-trimester exposure

Contrave contraindicated in pregnancy

Contrave weight management combination product contraindicated in pregnancy (weight loss during pregnancy inappropriate)

Late pregnancy exposure

Neonatal adaptation effects possible but less prominent than SSRIs

Weight-neutral profile relevance

During pregnancy, weight-neutral profile may be less advantageous (weight gain normal in pregnancy); SSRIs weight gain concerns less relevant

Smoking cessation in pregnancy

Bupropion for smoking cessation during pregnancy: risk-benefit consideration; some evidence smoking cessation more important than potential medication risk; specialist involvement

Untreated maternal depression risks

Substantial: preterm birth, low birth weight, impaired mother-infant bonding, postpartum depression, maternal suicide risk

✅ Pregnancy management approach

• Preconception planning: sertraline generally preferred SSRI for new depression therapy in pregnancy
• Established bupropion response: continuation reasonable if benefits outweigh risks
• Smoking cessation in pregnancy: risk-benefit assessment; some experts favour continued smoking cessation therapy given greater smoking risks
• Discuss with patient: reasonable evidence base overall
• Team approach: obstetrician + psychiatrist/prescriber + patient

💡 Pregnancy positioning

Bupropion during pregnancy is generally acceptable when clinical need justifies use though sertraline is preferred SSRI for new depression therapy in pregnancy. For patients established on bupropion with good response who become pregnant, continuation is often reasonable rather than switching (which risks decompensation). For smoking cessation in pregnancy specifically, some experts favour bupropion given substantial smoking-related pregnancy risks. Untreated maternal depression carries substantial risks and should not be underemphasized. Team approach with obstetrician + psychiatrist essential.

🔴 Breastfeeding considerations

Breast milk transfer

RID approximately 2 percent for parent bupropion; hydroxybupropion metabolite also transfers; infant plasma levels usually low

Infant seizure case reports

Rare case reports of infant seizures with maternal bupropion; possible causation debated but concern raised in LactMed

LactMed classification

Considered acceptable with monitoring; alternative preferred (sertraline) when possible

Chaudron and Schoenecker 2004

Case series and review; generally reassuring but concern remained

Preferred alternatives

Sertraline preferred SSRI for breastfeeding new therapy; extensive safety data

Continuing established therapy

Patients doing well on bupropion may continue with careful infant monitoring; assess mother-infant relationship benefit

Postpartum smoking cessation

Given smoking risks to infant (secondhand smoke, SIDS risk), bupropion smoking cessation in postpartum period may be reasonable with infant monitoring

💡 The cautious breastfeeding approach

Bupropion during breastfeeding warrants cautious approach given rare infant seizure case reports. For new SSRI therapy in breastfeeding mothers, sertraline is generally first choice. For mothers established on bupropion with good response, continuation is often reasonable with careful infant monitoring for seizure activity, unusual sleepiness, feeding difficulties. For postpartum smoking cessation, benefits of quitting smoking may outweigh theoretical concerns of bupropion during breastfeeding. Combined maternal-infant care with primary care, psychiatry, and pediatrics guides best decisions.

📋 Common adverse effect frequencies

Insomnia (35-40 percent)

Most common; activation effect; morning dosing reduces; typically improves over weeks

Headache (25-35 percent)

Common early therapy; usually improves

Dry mouth (15-25 percent)

Common but modest anticholinergic-like effect (not from muscarinic antagonism but from NDRI mechanism); less than TCAs

Nausea (10-15 percent)

Less than SSRIs; often improves; take with food

Anxiety or restlessness (5-10 percent)

Activation effect; may worsen preexisting anxiety; assess baseline anxiety

Tremor (5-10 percent)

Fine postural tremor; usually mild

Sweating (5-10 percent)

Common

Constipation (10 percent)

Modest

Weight gain

MINIMAL - weight-neutral or weight-reducing (typically 0-2 kg over year, sometimes weight loss); DISTINCTIVE advantage vs SSRIs (weight gain 1-3 kg) and other antidepressants

Sexual dysfunction

LOW - approximately 5-10 percent; DISTINCTIVE advantage vs SSRIs (30-50 percent)

Seizure risk

Dose-dependent signature concern; 0.1 percent at doses up to 300 mg XL; 0.4 percent at 300-450 mg; higher at higher doses

Blood pressure modest elevation

Some patients experience modest BP increase; monitor

💡 The distinctive trade-off profile

Bupropion represents distinctive trade-off among antidepressants: gain insomnia/activation and seizure risk in exchange for avoiding SSRI-typical problems (weight gain, sexual dysfunction, sedation, GI upset). This trade-off benefits some patients tremendously (weight/sexual/motivation-focused patients, SAD, smoking cessation) while being problematic for others (anxious patients, insomnia patients). Modern practice increasingly emphasizes matching antidepressant profile to patient rather than one-size-fits-all approach. For appropriate bupropion candidates, activating profile represents therapeutic advantage rather than adverse effect. For patients where activation would be problematic, alternatives (SSRIs, mirtazapine) are readily available. Understanding this trade-off framework guides appropriate patient selection and expectation-setting.

🚨 NDRI safety framework - distinctive concerns

Activation effects (signature)

Insomnia, anxiety, restlessness; opposite of SSRI activation is same concern; morning dosing reduces

Seizure risk (signature)

Dose-dependent; 0.1 percent up to 300 mg XL, 0.4 percent 300-450 mg; contraindicated seizure disorders

Weight-neutral profile (advantage)

Unique advantage vs other antidepressants; therapeutic for weight-concerned patients

Sexual function preservation (advantage)

5-10 percent sexual dysfunction vs SSRI 30-50 percent; distinctive advantage

Suicidality warning

Antidepressant class black box; particular concern under age 25

Discontinuation syndrome

Generally minimal (unlike SSRIs); mechanism different

Serotonin syndrome

Minimal risk given no serotonergic effect; MAOI contraindication for hypertensive rather than serotonergic concerns

Cardiovascular effects

Modest BP elevation possible; no cardiac conduction concerns unlike TCAs

Cognitive effects

Preserved or improved cognitive function; minimal emotional blunting unlike SSRIs

Overdose - seizure-focused

Primary overdose concern is seizures rather than TCA-like cardiotoxicity

💡 The distinct-from-SSRIs tolerability paradigm

Bupropion tolerability profile is essentially opposite to SSRIs: activating rather than sedating; weight-neutral rather than weight-gaining; sexual function preserving rather than sexual dysfunction-inducing; seizure risk rather than serotonin syndrome risk; no discontinuation syndrome complexity. This opposite profile makes bupropion valuable option for patients where SSRI adverse effects are problematic or where activating profile is therapeutically desired. For appropriate patient selection, this can produce substantially better patient experience than SSRI monotherapy. For patients where activation, insomnia, anxiety would be problematic, SSRIs or mirtazapine may be preferred. Combined with distinct FDA indications (depression, SAD, smoking cessation, weight management via Contrave), bupropion offers valuable and effective treatment with distinctive advantages.

⚡ Activation effect profile

Insomnia (35-40 percent - most common)

NDRI activation effect; usually early therapy; morning dosing reduces; often improves over 2-4 weeks with tolerance

Anxiety or restlessness (5-10 percent)

Activation effect; may worsen preexisting anxiety substantially; concerning for anxious depression patients

Agitation

Less common but possible; particularly with rapid dose escalation

Jitteriness or tremor

5-10 percent; usually fine postural tremor; may indicate excessive activation

Palpitations

Modest tachycardia possible; NDRI norepinephrine effect

Onset

Activation effects typically emerge first days-week of therapy

Tolerance development

Partial tolerance over 2-4 weeks for insomnia; anxiety effects may persist longer

✅ Activation management

• Morning dosing standard: avoid evening/bedtime dosing (would exacerbate insomnia)
• Slow titration: start 150 mg XL for 3-4 days before increasing; reduces initial activation
• Reassure about tolerance: activation usually improves over 2-4 weeks
• Avoid caffeine excess: additive activation
• Sleep hygiene emphasis: consistent sleep schedule, cool environment, no screens before bed
• Consider short-term sleep aid: melatonin, benzodiazepine short-term if persistent insomnia problematic
• Dose reduction: consider 150 mg XL if 300 mg problematic
• Anxious depression consideration: may need to switch to non-activating antidepressant if anxiety worsens substantially

💡 The activation as feature

Bupropion's activating profile is fundamental to its clinical utility - improves fatigue, motivation, and low energy that characterize many depression presentations. For patients with prominent hypersomnia, apathy, and anhedonia, activation is therapeutic goal. For patients with insomnia or anxious depression, activation may worsen these symptoms. Careful patient assessment before initiation helps predict activation impact. Combined with morning dosing (reducing insomnia risk), slow titration (allowing adaptation), and reasonable expectations (activation often improves with time), most patients tolerate bupropion well. For patients where activation persists problematically, alternatives (SSRIs, mirtazapine) with different activation profiles may be preferred.

🧠 Seizure risk profile

Historical context

Original 1985 approval; 1986 withdrawal due to seizure incidence at doses over 600 mg; 1989 reintroduction with 450 mg maximum reduced seizure incidence to acceptable range

Dose-response relationship

Approximately 0.1 percent at doses up to 300 mg XL; 0.4 percent at 300-450 mg; substantially higher above 450 mg; up to 4 percent at doses over 600 mg (original withdrawal doses)

Peak concentration relationship

Immediate release higher peaks = higher seizure risk than SR or XL formulations; explains dose limits particularly for IR

Alper 2007 analysis

Seizure incidence analysis across bupropion trials; confirmed dose-dependent risk pattern

Comparison with SSRIs

SSRIs have minimal seizure risk; bupropion seizure risk substantially higher though still relatively low at therapeutic doses

Risk factors

Personal or family seizure history; eating disorders (electrolyte disturbances); alcohol/benzo/barbiturate withdrawal; concurrent seizure-threshold-lowering medications; head trauma history; CNS tumors; increased age; low body weight

🔴 Contraindications (seizure risk)

• Seizure disorders: absolute contraindication regardless of etiology
• Anorexia nervosa or bulimia nervosa: current or prior; substantial seizure risk from electrolyte disturbances
• Abrupt discontinuation of alcohol, benzodiazepines, or barbiturates: active withdrawal states substantially lower seizure threshold
• Concurrent MAOI use: absolute contraindication

✅ Seizure risk management

• Comprehensive seizure history assessment before initiation
• Rule out eating disorders (particularly relevant for weight-conscious patients seeking bupropion)
• Rule out active alcohol/benzo/barbiturate withdrawal or history requiring careful consideration
• Review concurrent medications for seizure threshold effects
• Adhere to dose limits (450 mg absolute maximum)
• Prefer XL formulation (smoothest kinetics, lowest peak concentrations)
• Avoid concurrent tramadol (particularly problematic - substantial seizure threshold lowering)
• Educate patient about seizure symptoms and when to seek emergency care

💡 The manageable seizure risk

Bupropion's seizure risk represents managed rather than prohibitive concern for most patients. At therapeutic doses (up to 450 mg maximum) with appropriate patient selection, seizure incidence (approximately 0.1-0.4 percent) is acceptable given clinical benefits. The dose-response relationship and formulation-specific pharmacokinetics guide safe prescribing: XL formulation preferred, 450 mg absolute maximum, no more than 150 mg single IR dose, 8-hour SR interval. Contraindications (seizure disorders, eating disorders, alcohol/benzo withdrawal) are absolute and require careful history-taking. For appropriate patients avoiding these contraindications, bupropion can be used safely. Combined with patient education about seizure warning signs and appropriate emergency response, bupropion's seizure risk is genuinely manageable in real-world clinical practice.

⚖️ Weight-neutral profile

Typical weight change

Weight-neutral to modest weight loss; typically 0-2 kg over first year; some patients experience 3-5 kg weight loss

Mechanism

Dopamine reward effect reduces food-seeking; norepinephrine effect on energy expenditure; absence of histamine H1 antagonism (no appetite stimulation like SSRIs, mirtazapine); nicotinic effects reduce oral fixation

Comparison

Substantial advantage vs mirtazapine (3-6 kg gain), TCAs (3-6 kg gain), paroxetine (4-8 kg gain), other SSRIs (1-3 kg gain), olanzapine (5-10 kg gain)

Post-smoking cessation

Smoking cessation typically causes 2-4 kg weight gain; bupropion Zyban may mitigate quit-related weight gain

Contrave leverage

Combined with naltrexone for FDA-approved chronic weight management; approximately 4-6 percent additional weight loss vs placebo

🌟 Patient profiles benefiting from weight-neutral

• Obese patients or BMI over 30: avoiding further weight gain critical
• Diabetes mellitus type 2: weight gain worsens glucose control
• Metabolic syndrome: any weight gain problematic
• Cardiovascular disease: weight gain compounds cardiac risk
• Post-bariatric surgery: weight regain concern
• Weight-conscious patients: quality of life impact of weight gain
• Young active patients: body image concerns particularly adolescent-young adult
• Smoking cessation attempts: mitigate quit-related weight gain
• Depression with SSRI weight gain history: switch to weight-neutral option
• SAD with typical hyperphagia: counteracts SAD weight gain component

💡 The weight advantage clinical significance

Bupropion's weight-neutral profile provides substantial clinical advantage often underappreciated compared to sexual function preservation. For long-term antidepressant therapy (many patients requiring years), cumulative weight gain from SSRIs or other antidepressants can add 5-10+ kg over years - substantial impact on cardiovascular health, mobility, quality of life, and medication adherence. Weight-related discontinuation is common cause of antidepressant treatment failure. For weight-conscious patients or those with medical conditions where weight gain problematic (diabetes, obesity, metabolic syndrome, cardiovascular disease), starting bupropion may be preferable to starting SSRI then switching after weight gain develops. Modern practice increasingly recognizes weight neutrality as legitimate treatment consideration warranting bupropion as first-line for appropriate patients rather than reserved for second-line after SSRI trial.

❤️ Sexual function profile

Overall frequency

5-10 percent report sexual dysfunction - substantially less than SSRIs (30-50 percent)

Mechanism

Absence of serotonergic effect (no SERT inhibition); dopamine enhancement (DA promotes sexual response, contrary to 5-HT inhibitory effect); explains preservation of sexual function

Types of dysfunction (when present)

Modest reduced libido occasional; less than SSRI-typical delayed orgasm, anorgasmia, or erectile dysfunction

SSRI switch benefit

Patients experiencing SSRI sexual dysfunction often report substantial improvement when switched to bupropion

SSRI augmentation strategy

Clayton research supports adding bupropion 150-300 mg XL to SSRI patient experiencing sexual dysfunction while maintaining SSRI antidepressant efficacy

Comparison with mirtazapine

Both bupropion and mirtazapine have low sexual dysfunction rates; mirtazapine may cause weight gain while bupropion does not - complementary advantages

🌟 Patient profiles benefiting from sexual function preservation

• Younger sexually active patients: important quality-of-life consideration
• Patients with existing sexual dysfunction: don't worsen with SSRI
• Patients with SSRI-induced sexual dysfunction: switch or augmentation
• Patients where relationship intimacy important
• Recovery-focused patients where restoring full function includes sexuality
• Post-menopausal women with existing sexual concerns
• Men with erectile dysfunction history: don't worsen with SSRI
• Combined therapy for SSRI-induced sexual dysfunction: augmentation approach

💡 The sexual function advantage clinical significance

Bupropion's sexual function preservation is major clinical advantage frequently justifying its selection over SSRIs. Sexual dysfunction is leading cause of SSRI discontinuation and non-adherence. For patients where sexual function is important consideration, bupropion (or mirtazapine) provides substantially better profile than SSRIs. This advantage is particularly relevant for: younger patients; patients in intimate relationships; recovery-focused patients where full function restoration is treatment goal. Clayton research established bupropion as evidence-based augmentation for SSRI-induced sexual dysfunction - patients can maintain effective SSRI antidepressant while addressing sexual side effects through bupropion addition. Modern practice increasingly recognizes sexual function preservation as legitimate treatment consideration warranting bupropion as first-line for appropriate patients. Discussion of sexual function considerations should be routine part of antidepressant selection.

☠️ FDA black box suicidality warning

Origin

2004 initial pediatric warning; 2007 expanded to young adults through age 24

Absolute risk

Approximately 4 per 100 exposed vs 2 per 100 placebo (absolute increase 2 per 100)

Age gradient

Highest concern under age 25

Timing

Highest risk first 4 weeks and during dose changes

Zyban smoking cessation

Boxed warning originally applied to Zyban given historical neuropsychiatric concerns; EAGLES trial 2016 demonstrated smoking cessation neuropsychiatric safety; FDA removed Zyban boxed warning 2016

Depression indication - warning retained

Boxed warning remains for depression indication given depression itself carries suicide risk

Overdose safety perspective

Bupropion overdose primarily produces seizures rather than cardiac toxicity (unlike TCAs); overall safer than TCAs but seizure concern exists

👉 Monitoring protocol (under age 25)

• Baseline suicidality assessment
• Weekly visits first 4 weeks
• Biweekly visits weeks 5-8
• Monthly visits weeks 9-12
• Then routine schedule with vigilance
• Family and patient awareness of warning signs
• Written safety plan
• Emergency contact information
• Prompt psychiatric consultation for concerns

💡 Clinical context - EAGLES trial reassurance

The Anthenelli EAGLES trial 2016 (Lancet) was landmark study of neuropsychiatric safety of smoking cessation pharmacotherapies including bupropion. Trial demonstrated no substantial increase in serious neuropsychiatric events with bupropion (or varenicline) vs placebo or NRT in smokers without or with psychiatric history. This led FDA to remove Zyban boxed warning for smoking cessation indication in 2016 - important safety reassurance. For depression indication, boxed warning remains reflecting antidepressant class effect. Untreated depression carries substantial suicide risk itself - treatment appropriately with reasonable monitoring generally provides best outcomes. Combined with age-appropriate monitoring, safety plan development, family involvement when needed, and prompt access to psychiatric care, appropriate bupropion use in young patients is feasible.

🔄 Discontinuation syndrome features

Frequency

Generally minimal (5-10 percent report symptoms); substantially less than SSRIs (30-40 percent), paroxetine (30-50 percent), venlafaxine

Common symptoms

Mild fatigue, low mood return, sleep changes, headache; less prominent than SSRI FINISH mnemonic symptoms

Distinguish from relapse

Depression relapse: persistent low mood, anhedonia. Discontinuation: transient physical symptoms

Zyban discontinuation

Smoking cessation patients discontinuing bupropion generally experience minimal withdrawal from bupropion itself; smoking relapse remains concern requiring behavioural support

SAD discontinuation

Spring taper acceptable when appropriate; year-round continuation option if pattern warrants

✅ Taper protocol

• Short-term use (weeks): may stop without taper
• Longer-term use (months+): gradual taper over 2-4 weeks reasonable
• Depression: standard taper: reduce XL 300 mg to 150 mg for 1-2 weeks, then discontinue
• Smoking cessation Zyban: after 7-12 weeks treatment, may taper or discontinue based on abstinence stability
• Symptom-based adjustment: pause or slow if symptoms emerge
• Educate about expected symptoms: distinct from depression relapse

💡 The gentler discontinuation advantage

Bupropion's minimal discontinuation syndrome is another distinctive advantage over SSRIs and SNRIs. For patients likely to need trial discontinuation or complete discontinuation over time, gentler withdrawal profile represents practical advantage. This contrasts with paroxetine (worst discontinuation syndrome), venlafaxine (severe discontinuation), or fluvoxamine (moderate). For patients where medication discontinuation possibility is important, bupropion's gentler profile may be selection consideration. Combined with weight-neutral, sexual-function-preserving profile, bupropion provides distinctive tolerability advantages throughout treatment lifecycle from initiation to potential discontinuation.

🔥 Minimal serotonin syndrome risk

Mechanistic basis

Bupropion is NDRI (norepinephrine + dopamine reuptake); NO significant serotonin transporter inhibition; NO significant 5-HT receptor effects

Practical implications

Combinations with serotonergic drugs are generally safe from serotonin syndrome perspective; bupropion + SSRI augmentation (sexual dysfunction management) common and safe

Contrast with TCAs and SNRIs

Unlike TCAs, SNRIs, or SSRIs which have substantial serotonergic effects requiring caution with serotonergic combinations, bupropion is essentially safe from this perspective

Triptans, tramadol combinations

Less concerning than with SSRIs from serotonin syndrome perspective; however, other concerns may apply (tramadol seizure threshold lowering + CYP2D6 interaction)

🔴 MAOI contraindication - different reason

MAOI + bupropion mechanism

Contraindication is due to hypertensive crisis risk (norepinephrine and dopamine accumulation with MAO inhibition) rather than serotonin syndrome; still absolute contraindication

14-day washout required

Both directions - after MAOI stopping before bupropion; and after bupropion before MAOI

Linezolid, methylene blue

MAOI-like activity; same contraindication concern

💡 The serotonin syndrome absence advantage

Bupropion's lack of serotonergic activity provides practical advantages: (1) safer combination with other serotonergic drugs (though other interaction concerns may apply); (2) no need for washout when switching from/to non-MAOI serotonergic drugs; (3) safer choice for patients who developed serotonin syndrome from previous serotonergic medications; (4) enables bupropion+SSRI augmentation for sexual dysfunction without serotonin syndrome concern. This represents advantage over TCAs and SNRIs which have substantial serotonergic effects. However, MAOI contraindication remains absolute for different mechanistic reason (hypertensive crisis from NE/DA accumulation). Understanding this mechanistic distinction guides appropriate combination therapy decisions.

💓 Cardiovascular effect profile

Blood pressure elevation

Modest BP increase possible (mean 2-3 mmHg systolic); NE effect; substantially more concerning in existing hypertension particularly uncontrolled

Heart rate

Modest tachycardia possible; NE effect; usually clinically insignificant

QT prolongation

Not clinically significant at therapeutic doses; unlike citalopram or TCAs

QRS/conduction

NO sodium channel effects; unlike TCAs; no conduction concerns

Chan JACC 2003

Bupropion cardiovascular safety generally favourable

Post-MI use

Less established than sertraline (SADHART trial); sertraline generally preferred for post-MI depression; bupropion may be reasonable in specific circumstances

Combined with nicotine transdermal (smoking cessation)

Modest additive BP elevation possible; often used together; monitor BP

⚠️ Cardiovascular concerns and monitoring

• Baseline blood pressure and heart rate
• Uncontrolled hypertension - avoid or use with caution
• Well-controlled hypertension - generally acceptable with monitoring
• BP monitoring during titration and periodically
• Recent MI - alternative preferred (sertraline SADHART)
• Heart failure - generally acceptable but monitor
• Cardiac arrhythmias - generally acceptable given no QT/QRS effects
• Concurrent nicotine patches (smoking cessation) - additive BP effects; monitor
• Contrave contraindicated in uncontrolled hypertension

💡 The favourable cardiac safety

Bupropion's cardiovascular profile is generally favourable - much safer than TCAs (which have substantial cardiac conduction concerns), comparable to SSRIs, without citalopram's QT concerns. Main cardiovascular consideration is modest BP elevation from NE effect. For patients with hypertension, well-controlled BP allows safe bupropion use with monitoring; uncontrolled hypertension warrants avoidance or careful use. Contrave weight management combination has more prominent BP considerations given naltrexone effect and higher bupropion doses. Combined with weight-neutral profile (avoiding weight gain-related cardiovascular risk over years), bupropion may be favourable choice for cardiovascular-vulnerable patients requiring antidepressant. For post-MI depression specifically, sertraline has strongest evidence (SADHART); bupropion reasonable alternative in specific circumstances.

🧠 Cognitive effects

Attention and concentration

Generally preserved or improved; NDRI mechanism supports attention (basis for adult ADHD off-label utility)

Executive function

Generally preserved; dopamine effect supports executive function

Memory

Generally preserved; no significant anticholinergic burden unlike TCAs and paroxetine

Cognitive fogginess

Minimal; unlike SSRIs which some patients report as cognitive dulling

Elderly cognitive concerns

Generally cognition-preserving in elderly; important advantage over anticholinergic medications

😐 Emotional range preservation

Frequency of emotional blunting

Minimal (5-15 percent) - substantial advantage over SSRIs (30-60 percent report some blunting)

Mechanism

Absence of serotonergic effect explains lack of emotional blunting typical of SSRIs; dopamine effect actually enhances reward processing and emotional engagement

Patient reports

Patients often report feeling "more like themselves" on bupropion compared to SSRIs; preserved capacity for both positive and negative emotions

Creativity and passion preservation

Particularly valuable for creative professionals or patients where emotional depth important

💡 The cognitive and emotional preservation advantage

Bupropion's cognitive and emotional preservation profile represents distinctive advantage often underappreciated. For patients concerned about emotional blunting on SSRIs (increasingly recognized issue), bupropion provides alternative that preserves emotional range while providing antidepressant effect. For patients requiring cognitive sharpness (professionals, students, older adults concerned about cognitive function), bupropion's activating NDRI profile supports rather than impairs cognition. Combined with lack of anticholinergic burden (unlike paroxetine, TCAs), bupropion is often cognitive-friendly antidepressant choice. Modern practice increasingly recognizes cognitive and emotional preservation as legitimate treatment considerations - bupropion offers evidence-based approach when these factors are important.

🏥 Overdose profile - seizure-focused

Primary overdose concern

Seizures - dose-dependent risk; can be repeated or status epilepticus in severe cases

Threshold for toxicity

Doses over 900 mg produce moderate toxicity with seizure risk; over 1500 mg substantial; over 3000 mg severe with high mortality

Cardiovascular effects

Modest tachycardia and hypertension; unlike TCAs, no QRS widening or ventricular arrhythmias; sodium channel spared

CNS effects

Agitation, hallucinations, altered mental status; seizures can be severe

Comparison with TCAs

Safer than TCA overdose (no cardiotoxicity); Buckley BMJ 2002 fatality index intermediate between SSRIs (safest) and TCAs (most concerning)

Comparison with SSRIs

Less safe than pure SSRIs due to seizure concern; still substantially safer than TCAs

✅ Overdose management

• Emergency stabilization: ABC, IV access, cardiac monitoring, seizure precautions
• Activated charcoal if within 1-2 hours and airway protected
• Continuous cardiac and seizure monitoring - ICU care for severe ingestions
• Benzodiazepines for seizure activity - first-line treatment; may need repeated doses or continuous infusion for status epilepticus
• Airway protection if depressed consciousness
• Supportive care with IV fluids
• BP management if severely elevated
• Not effectively dialysed (large Vd, high protein binding)
• Extended monitoring - 24 hours minimum given delayed seizure risk
• Psychiatric evaluation before discharge

💡 The seizure-focused overdose profile

Bupropion overdose safety profile is unique among antidepressants - seizures as primary concern rather than cardiac toxicity (TCAs) or serotonin syndrome (SSRIs). Overall safer than TCAs given absence of cardiac conduction effects, but seizure risk requires benzodiazepine-focused management approach. For patients where suicide risk is concern, bupropion overdose safety consideration includes: (1) seizure risk requires seizure management preparation; (2) less lethal than TCA overdose but not as safe as SSRI overdose; (3) prescribing modest quantities appropriate for suicidal patients; (4) safety planning and family involvement. Combined with monitoring, appropriate patient selection avoiding highest suicide risk when possible, bupropion can be used safely across depression severity spectrum with reasonable safety precautions.

📈 Monitoring parameters by indication

Depression severity

PHQ-9 at baseline and follow-up; response = 50 percent reduction; remission = PHQ-9 less than 5

SAD symptoms

Structured Interview Guide for the Hamilton Depression Rating Scale Seasonal Affective Disorder version (SIGH-SAD); patient diary

Smoking cessation outcomes

Abstinence rate; cigarette count; carbon monoxide monitor when available; craving assessment

Suicidality

Assessment at every visit particularly under age 25; first weeks and dose changes

Adverse effects

Systematic screening: insomnia, anxiety/activation, headache, dry mouth, weight (usually neutral or improving), sexual function (usually preserved)

Blood pressure monitoring

Baseline and periodic monitoring; particularly important patients with hypertension or on Contrave

Seizure surveillance

Educate patient about seizure symptoms; immediate evaluation if suspected seizure activity; ensure dose limits

Drug interaction assessment

Ongoing review of medications; particular attention to CYP2D6 substrates and seizure threshold drugs

💡 The straightforward monitoring

Bupropion monitoring is generally straightforward reflecting reasonable safety profile: symptom scale outcome assessment, suicidality vigilance particularly first weeks, blood pressure monitoring (particularly for hypertensive patients or Contrave), seizure risk surveillance through appropriate patient selection and dose limits, medication interaction assessment. No routine laboratory monitoring required. No routine ECG needed unlike TCAs. Baseline contraindication assessment (eating disorders, alcohol/benzo withdrawal history) most important safety consideration. Combined with symptom-focused outcome assessment, structured follow-up guides safe and effective bupropion therapy.

📦 Storage requirements

Temperature

Room temperature 20-25°C (68-77°F); brief excursions 15-30°C acceptable

Humidity

Below 60 percent relative humidity; avoid humid environments

Light exposure

Protect from direct sunlight; original packaging appropriate

Container

Keep in original bottle with cap tightly closed

Wellbutrin XL - critical

Do NOT crush, chew, or split XL tablets - destroys extended-release mechanism producing higher peak concentrations and increased seizure risk; swallow whole with water

Wellbutrin SR - important

SR tablets can be halved if scored (150 mg strength) but preferred to use lower strength; do not crush

Zyban - do not crush

Zyban is SR formulation; same crushing prohibition as SR

Contrave - do not crush

Extended-release combination tablet; swallow whole

Shelf life

Typically 24-36 months from manufacture; check expiration date

Child safety

Child-resistant caps essential; particularly important given seizure risk with pediatric ingestion

Disposal

Take-back programs, pharmacy return, or approved disposal methods; do not flush

✅ Storage practical tips

• Store in bedroom or kitchen cabinet away from moisture (not bathroom)
• Keep out of direct sunlight or hot areas
• Never transfer to unmarked containers
• Keep separate from other medications
• Critical: NEVER crush XL or SR tablets - destroys release mechanism, increases seizure risk
• Store away from children and pets
• Check periodically for expiration and physical changes
• Travel: keep in original container with prescription label
• Return excess to pharmacy at end of therapy

🗣️ Essential counselling points

Treatment expectations by indication

Depression: energy/motivation improvement early (1-2 weeks), full effect 4-6 weeks; SAD: 2-4 weeks response; Smoking cessation: start 1-2 weeks before quit date, 7-12 weeks total

Morning dosing standard

Take in morning; avoid evening/bedtime given activating profile; consistent daily timing

Distinctive activating profile

Unlike SSRIs, bupropion is activating - improves energy and motivation; may cause initial insomnia or anxiety that usually improves over weeks

Weight-neutral advantage

Unlike other antidepressants, bupropion is weight-neutral or slightly weight-reducing; important consideration if weight is concern

Sexual function preservation

Unlike SSRIs, bupropion typically preserves sexual function; important consideration if this concern

Seizure risk awareness

Signature safety concern; follow dose instructions carefully; NEVER exceed 450 mg/day; report any seizure activity immediately

DO NOT crush XL or SR tablets

Critical - crushing destroys release mechanism, increases seizure risk substantially; swallow whole

Alcohol restriction

Substantial limitation; abrupt discontinuation of heavy alcohol use particularly dangerous with bupropion (seizure risk)

Blood pressure monitoring

May cause modest BP elevation; particularly important if hypertensive; report severe headaches or new BP concerns

Suicidality watch (under 25)

Especially first weeks; family aware; contact clinician for concerning changes

Do not stop suddenly

Taper gradually for chronic use though discontinuation syndrome is generally minimal

Drug interactions

Inform all providers; MAOI absolute avoid; bupropion is potent CYP2D6 inhibitor affecting many medications; particular concern with tamoxifen (breast cancer)

Missed dose

Take as soon as remembered same day but ONLY if several hours before next dose; skip if closer to next dose; NEVER double dose (seizure risk)

Smoking cessation counselling (Zyban)

Set quit date 1-2 weeks after starting; continue smoking during first week while medication builds; combine with behavioural counselling; may combine with NRT

🔴 When to seek immediate care

• Suicidal thoughts or plans
• CRITICAL: Any seizure activity - discontinue and emergency evaluation
• Severe agitation or extreme restlessness
• Severely elevated blood pressure or severe headache
• Chest pain or palpitations
• Severe allergic reaction (rash, difficulty breathing)
• New mania or hypomania symptoms
• Any suspected overdose
• Severe cognitive changes or confusion

🚫 Absolute contraindications

Seizure disorder

History of any seizure disorder - absolute contraindication given seizure threshold lowering effect

Anorexia nervosa or bulimia nervosa (current or prior)

Substantial seizure risk from electrolyte disturbances associated with eating disorders

Abrupt discontinuation of alcohol, benzodiazepines, or barbiturates

Active withdrawal states substantially lower seizure threshold

Concurrent MAOI use

Severe hypertensive reactions possible; 14-day washout both directions

Known hypersensitivity

Prior severe reaction to bupropion or excipients

Concurrent linezolid or IV methylene blue

MAOI-like activity; hypertensive reaction concern

Ritonavir + efavirenz combination

Substantially increases bupropion levels; avoid combination

⚠️ Relative contraindications

Uncontrolled hypertension

BP elevation may worsen; control hypertension first; monitor closely

Recent myocardial infarction

Sertraline preferred for post-MI depression (SADHART evidence)

Anxious depression with prominent anxiety

Activating profile may worsen anxiety; SSRI/mirtazapine may be preferred

Persistent insomnia

Activating profile may worsen; mirtazapine may be preferred for depression+insomnia

Concurrent tamoxifen (breast cancer)

CYP2D6 inhibition reduces tamoxifen effectiveness; use venlafaxine or escitalopram

Concurrent codeine, tramadol, hydrocodone

Reduced analgesic effect; alternative opioid selection

Concurrent tramadol (seizure)

Substantially lowered seizure threshold with combination

CNS tumor or serious head injury

Increased seizure risk

Concurrent TCAs

Substantial CYP2D6 interaction requires TCA dose reduction 50-70 percent

Bipolar disorder without mood stabilizer

Risk of mania induction (though possibly lower than SSRIs)

Severe hepatic impairment

Substantial dose reduction; every other day dosing

Pregnancy

Category C; sertraline often preferred for new therapy

Breastfeeding

Rare infant seizure case reports; sertraline preferred SSRI

💡 Pre-prescription checklist

Before initiating Wellbutrin: (1) Verify MAOI absence and 14-day washout; (2) Rule out seizure disorder - personal or family history assessment; (3) Rule out current or prior eating disorders (anorexia, bulimia) - critical safety check; (4) Assess alcohol/benzodiazepine use - rule out active withdrawal or recent abrupt cessation; (5) Comprehensive medication review including seizure threshold drugs, CYP2D6 substrates (tamoxifen especially in women), tramadol/codeine; (6) Assess for anxious depression or prominent insomnia - may not be ideal candidate; (7) Baseline blood pressure and assess for hypertension control; (8) Confirm no bipolar disorder without mood stabilization; (9) Assess suicide risk; (10) Evaluate hepatic function; (11) Discuss pregnancy plans if relevant; (12) Determine appropriate indication and formulation (XL for depression/SAD, SR/Zyban for smoking cessation); (13) Establish monitoring plan. Structured approach ensures safety while optimising therapeutic benefit.

✅ When Wellbutrin is particularly well-suited

Bupropion is particularly appropriate for: (1) depression with prominent fatigue, low motivation, apathy - activation therapeutic; (2) weight-conscious patients or patients with obesity, diabetes, metabolic syndrome - weight-neutral advantage; (3) sexual function important - minimal sexual dysfunction; (4) smoking cessation with or without concurrent depression (Zyban) - dual benefit possibility; (5) seasonal affective disorder (Wellbutrin XL) - FDA-approved with SAD-specific profile match; (6) SSRI-intolerant patients - different mechanism, different side effect profile; (7) SSRI-induced sexual dysfunction augmentation (Clayton research); (8) SSRI-induced weight gain - switch to weight-neutral option; (9) adult ADHD (off-label) - non-controlled substance alternative to stimulants; (10) treatment-resistant depression augmentation; (11) elderly depression (Beers-acceptable, weight-neutral advantages); (12) depression with anhedonia - dopamine effect on reward. Less optimal for: (1) anxious depression with prominent anxiety - activation may worsen; (2) persistent insomnia patients - activation may worsen; (3) seizure disorder history - contraindicated; (4) current or prior eating disorders - contraindicated; (5) active alcohol/benzo withdrawal - contraindicated; (6) breast cancer patients on tamoxifen - use venlafaxine/escitalopram; (7) patients on codeine/tramadol/hydrocodone for pain - reduced analgesia; (8) uncontrolled hypertension; (9) post-MI recent - sertraline preferred (SADHART); (10) pregnancy - sertraline often preferred; (11) breastfeeding - sertraline preferred. Alternatives include: SSRIs (sertraline, escitalopram) for depression first-line general; mirtazapine for depression+insomnia or appetite loss; SNRIs for depression+pain; light therapy for SAD first-line; varenicline or NRT for smoking cessation alternatives. Individual patient factors, comorbidities, and treatment goals guide selection. In appropriate patients, bupropion provides highly effective treatment with distinctive advantages including weight-neutral profile, sexual function preservation, activation effect, smoking cessation efficacy, and SAD approval.